Distribution Solutions Group (DSGR) Q4 2025 earnings review
Top-Line Stalls, Margins Compress Across the Board
Distribution Solutions Group ended 2025 on a weak note. Revenue growth decelerated sharply to a flat 0.2% YoY, and organic average daily sales ground to 0.0%. More concerning is the bottom line: Adjusted EBITDA margins reversed from 9.3% a year ago to 7.4%, with severe margin contraction observed across every single operating segment. Management cited product mix shifts, healthcare costs, and leadership investments. While robust operating cash flow ($84M for the year) and a newly expanded $1.1B credit facility provide a strong safety net, the Q4 P&L reflects significant execution and macro headwinds.
🐂 Bull Case
Generated $83.8M in operating cash flow for the year (up 48% YoY). With $469M in total available liquidity and a newly extended credit facility through 2030, the balance sheet is primed for continued M&A.
Management notes they are beginning to see backlogs build and improved momentum in weekly sales cadence, suggesting the Q4 stagnation may be a trough rather than a new baseline.
🐻 Bear Case
There was nowhere to hide in Q4. Every segment saw Adjusted EBITDA margins fall YoY, highlighted by a brutal 310 bps drop at Lawson Products (9.8% to 6.7%).
After posting 6.0% organic average daily sales growth in Q3, Q4 organic growth decelerated to exactly 0.0%, reflecting a tough macro environment and soft end-markets.
⚖️ Verdict: 🔴
Bearish. Management praised the 'strength of our operating model,' but the data contradicts this narrative: a 0.2% revenue print combined with a 190 bps compression in consolidated EBITDA margins reveals a business struggling to flex its operating leverage in a soft macro environment.
Key Themes
Broad-Based Margin Contraction Contradicts 'Execution' Narrative
Management's press release cited the 'strength of our operating model and execution,' but the segment data tells a Reversing story. Adjusted EBITDA margins fell uniformly: Lawson (9.8% to 6.7%), Gexpro (13.3% to 11.7%), TestEquity (7.8% to 6.4%), and Canada (7.2% to 6.6%). This indicates systemic, portfolio-wide pressure rather than isolated, segment-specific blips.
Organic Sales Growth Decelerating to Zero
The company’s organic average daily sales growth fell to 0.0% in Q4, a sharp Decelerating trend from 6.0% in Q3 and 3.3% in Q2. Total revenue was functionally flat (+0.2%), kept afloat only by $1.7M in incremental revenue from acquisitions closed late last year.
Elevated SG&A and Healthcare Costs
The company cited timing of employee-related costs, specifically healthcare benefits, and leadership talent investments as primary culprits for the margin miss. Selling, general and administrative expenses rose to $149.9M (31.1% of revenue) from $139.9M (29.1% of revenue) a year ago. Without top-line growth to absorb these costs, they hit the bottom line directly.
Robust Free Cash Flow Conversion
Despite P&L weakness, cash generation remains a Stable driver. DSG generated $83.8M in operating cash flow for the year, up from $56.5M in 2024. Working capital management was highly effective, with net working capital ending flat YoY at $473.5M despite the larger revenue base.
Balance Sheet Refinancing Unlocks Dry Powder
During Q4, DSG expanded its credit facility through 2030, securing $700M in term debt and raising its revolving credit capacity from $255M to $400M. Ending the year with a minimal revolver balance and $469M in total liquidity, DSG is heavily armed to resume its aggressive M&A strategy if valuations become attractive.
2026 Backlog Recovery
While giving no formal quantitative guidance, CEO Bryan King noted Accelerating forward indicators, stating the company is 'beginning to see backlogs build and improved momentum in our weekly sales cadence' looking ahead to 2026.
Test & Measurement Mix Shifts
Margin pressure at TestEquity was explicitly blamed on shifts in the product and solutions mix. As customers pivot purchasing behaviors within electronic test and measurement hardware, DSG is selling a higher volume of structurally lower-margin items, dragging the segment's margin from 7.8% down to 6.4%.
Challenging Macro Environment
Management acknowledged a 'challenging macroeconomic environment affecting most U.S. companies.' This macro softness is directly manifesting in delayed project starts and cautious MRO ordering behavior, suppressing the top line across the Lawson and Canada segments.
Other KPIs
A severe GAAP loss for Q4, though an improvement from the $(25.9)M loss in 24Q4 (which was dragged down by a $30.1M tax expense). Operating income fell 61.5% YoY to $7.7M, showing that operational profitability worsened significantly, offset only by a normalized tax rate.
Deployed excess cash flow effectively to retire shares at an average price of $30.26. $3.5M of this was executed in Q4, maintaining a Stable cadence of returning capital to shareholders when M&A targets are not immediate.
Stable. The company maintained its 3.5x leverage ratio exiting the year, exactly matching the target and historical levels, proving disciplined integration despite previous debt-funded acquisitions.
Guidance
Management did not issue quantitative guidance for FY26 in the press release. They indicated an Accelerating environment, citing building backlogs and improved weekly sales cadence, while emphasizing a focus on 'building structurally higher-margin businesses' going forward.
Key Questions
Structural vs. Transient Margin Compression
Adjusted EBITDA margins compressed across all four segments in Q4. Exactly how much of the 190 bps consolidated drop was due to one-time 'leadership talent investments' versus structural 'product and solutions mix' shifts that will persist into 2026?
Healthcare Cost Spikes
You noted the timing of employee healthcare benefits pressured margins. Are these costs resetting at a permanently higher base for FY26, or was there an unusual Q4 true-up?
Canada Branch Division Weakness
Canada segment revenue fell ~7% YoY. How much of this is tied to the previously discussed 'economic anxiety around tariffs' versus project roll-offs, and what is the timeline to return this segment to growth?
M&A vs. Buybacks
With $469M in liquidity and an expanded credit facility, yet recent margin struggles integrating the 2024 acquisitions, will you prioritize internal margin repair and share buybacks in H1 2026 over new M&A?